Skip to main navigation

About
Platform
Pipeline
- MDNA11
- BiSKITs
- MDNA55
Clinical Trials
Investor Relations
- News & Events
- Stock Information
  - Stock Quote & Chart
  - Analyst Coverage
- Corporate Governance
- Financials & Filings
  - SEC Filings
  - Financial Reports
- IR Resources

Careers
Contact

Investor Relations

Scientific Publications

Publications

Categories

Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial

Source

Sampson et al., Neuro-Oncology 2023

Phase II trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment

Source

Stephen J. Bagley, Neuro-Oncology 2023

Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

Source

Merchant et al., Journal for Immunotherapy of Cancer 2022

Leveraging external data in the design and analysis of clinical trials in neuro-oncology

Source

Rahman et al., Lancet 2021

Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma

Source

Ellingson et al., Clinical Cancer Research 2021

Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma

Source

Mohan et al., Surgical Neurology International 2021

Exploiting a natural conformational switch to engineer an interleukin-2 “superkine”

Source

Levin et al., Nature 2012

RSS Feeds

Print Page

Email Alerts

Document Request

© Copyright 2024 Medicenna Therapeutics

Terms of Use
Privacy Policy

Follow Us